Valeria Poli

Biotechnology Research Center — IR

Medicine · Health Sciences

75h-index22.3kcitations258works1.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cytokine Signaling Pathways and Interactions(90), Immunotherapy and Immune Responses(20), Immune Response and Inflammation(19), interferon and immune responses(18), NF-κB Signaling Pathways(17)

Publications257 total

A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance
Proceedings of the National Academy of Sciences·2025· 3 citedOpen Access
From Coexpression to Causality: Defining Functional Hub Genes in Basal-like Breast Cancer Networks
2025Open Access
A TARGETED COMBINATION THERAPY ACHIEVES EFFECTIVE PANCREATIC CANCER REGRESSION AND PREVENTS TUMOR RESISTANCE
2025· 2 citedOpen Access
Correction: Cross-tissue gene expression interactions from bulk, single cell and spatial transcriptomics with crossWGCNA
BMC Genomics·2025Open Access
Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts
Journal of Visualized Experiments·2025
Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
Journal of Visualized Experiments·2025
Cancer-associated fibroblast driven paracrine IL-6/STAT3 signaling promotes migration and dissemination in invasive lobular carcinoma
Breast Cancer Research·2025· 2 citedOpen Access
Cross-tissue gene expression interactions from bulk, single cell and spatial transcriptomics with crossWGCNA
BMC Genomics·2025· 1 citedOpen Access
Europe must become a research epicentre as US system gets undermined
Nature·2025
Novel FAP-Targeted Heptamethine Cyanines for NIRF Imaging Applications
Molecular Pharmaceutics·2025· 5 citedOpen Access
A037 Decoding neuronal vulnerability: integrative analysis of D1r- and D2r-Msns responses in Huntington’s disease
2024Open Access
A novel function of STAT3β in suppressing interferon response improves outcome in acute myeloid leukemia
Cell Death and Disease·2024· 8 citedOpen Access
RICTOR/mTORC2 downregulation in BRAFV600E melanoma cells promotes resistance to BRAF/MEK inhibition
Molecular Cancer·2024· 8 citedOpen Access
Supplementary Table 1 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
2024Open Access
Data from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
2024Open Access
Supplementary Figure 3 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
2024Open Access
Supplementary Figure 3 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
2024Open Access
Supplementary Figure 5 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
2024Open Access
Data from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
2024Open Access
Supplementary Figure 6 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
2024Open Access
page 1 of 13Next →

Frequent Co-authors

Gennaro Ciliberto(6), Tonino Alonzi(5), Elena Fattori(4), Lidia Avalle(4), Rebecca Taub(3), Carlo Toniatti(3), Diego Maritano(3), James Turkson(3), Christine J. Watson(3), Silvia Tininini(3), Sara Pensa(3), Richard Moriggl(3), Robert Eferl(3), Harald Esterbauer(3), Lukas Kenner(3), Annalisa Camporeale(3), Drew E. Cressman(2), Linda E. Greenbaum(2), Pietro Ghezzi(2), Raffaella Faggioni(2)